Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8144438 | PMC |
| http://dx.doi.org/10.3389/fcimb.2021.655363 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Measles: More than just a rash.
Nursing
December 2024
Dorothy Borton is an independent infection prevention consultant based in Philadelphia, Pa., and a member of the Nursing2024 Editorial Board.
Measles (rubeola) cases and outbreaks have increased worldwide in 2023 and 2024. This article provides a comprehensive overview of the global resurgence of measles cases, highlighting the critical role of vaccination in preventing outbreaks. It also discusses the factors contributing to declining vaccination rates, the implications for public health, and immediate infection control measures in the event of suspected cases.
View Article and Find Full Text PDFImmunogenomic determinants of exceptional response to immune checkpoint inhibition in renal cell carcinoma.
Nat Cancer
January 2025
Department of Hematopoietic Biology and Malignancy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Immune checkpoint inhibitors can lead to 'exceptional', durable responses in a subset of persons. However, the molecular basis of exceptional response (ER) to immunotherapy in metastatic clear cell renal cell carcinoma (mccRCC) has not been well characterized. Here we analyzed pretherapy genomic and transcriptomic data in treatment-naive persons with mccRCC treated with standard-of-care immunotherapies: (1) combination of programmed cell death protein and ligand 1 (PD1/PDL1) and cytotoxic T lymphocyte-associated protein 4 inhibitors (IO/IO) or (2) combination of PD1/PDL1 and vascular endothelial growth factor (VEGF) receptor inhibitors (IO/VEGF).
View Article and Find Full Text PDFObjectives: COVID-19 vaccine was rolled out for the public in August 2021 in Zamfara state, Northen Nigeria. We determined the factors influencing COVID-19 vaccine acceptance.
Settings: We executed a community-based analytical cross-sectional study during the first 4 months of the second phase of the COVID-19 (Oxford/AstraZeneca) mass vaccination campaign in Zamfara state.
Acute kidney injury following CAR-T cell therapy: a nephrologist's perspective.
Clin Kidney J
January 2025
Department of Medicine, Universidad Autonoma de Madrid and IIS-Fundacion Jimenez Diaz, Madrid, Spain.
Chimeric antigen receptor T (CAR-T) cell therapy, an emerging personalized immunotherapy for various haematologic malignancies, autoimmune diseases and other conditions, involves the modification of patients' T cells to express a chimeric antigen receptor that recognizes tumour or autoimmune cell antigens, allowing CAR-T cells to destroy cancerous and other target cells selectively. Despite remarkable clinical improvements in patients, multiple adverse effects have been associated with CAR-T cell therapy. Among the most recognized adverse effects are cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome and tumour lysis syndrome.
View Article and Find Full Text PDFOptimal use, combinations, and sequencing of therapies in advanced prostate cancer.
Expert Rev Clin Pharmacol
January 2025
Division of Oncology Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!